Long reads, slow takes.

lifestyle· November 4, 2026

When the heat comes on

The radiator clicks on sometime around now, and the air in the room changes before the weather outside does. A note on winter skin as a question about the room, not the regimen.

research· November 2, 2026

A youth protein, and the brain's cleanup crew

A protein called TIMP2, first pulled out of umbilical-cord plasma years ago, turns out to keep the brain's immune cells doing their job. What a 2026 mouse study showed, and the long distance between a protein in a mouse and anything a person could use.

explainer· October 30, 2026

What Matrixyl actually is, and the false alarm it sends your skin

Matrixyl is a lab-made copy of a collagen fragment that the skin reads as a signal to rebuild. A plain look at matrikines, the fatty tail that gets it through the barrier, and why the evidence stays modest and mostly industry-funded.

lifestyle· October 28, 2026

Carry something heavy

Almost nothing in modern life has to be carried anymore, so we pay for the privilege at a gym. But the season still hands you the real thing: groceries up the stairs, wood to the door, bags in from the cold. A note on the load you didn't schedule.

research· October 26, 2026

The dose on the label, and the dose in the vial

Independent testing of gray-market peptides keeps finding products that hold a fraction of the labeled dose, the wrong molecule, or outright contaminants. Why the evidence about a compound and the evidence about the vial in your hand are two separate questions.

explainer· October 23, 2026

What MariTide actually is, and the receptor it blocks instead of boosts

MariTide is an experimental once-monthly obesity drug built from two GLP-1 peptides bolted onto an antibody. The strange part is the second receptor: where tirzepatide switches GIP on, MariTide switches it off, and both lose weight. What the Phase 2 data showed, and why the field can't fully explain the paradox.

lifestyle· October 21, 2026

The short side of the year

By late October the light has gone short and low, and the year starts rationing the one thing we named ourselves after. A note on the lit middle of the day, and why it's worth going out to meet.

research· October 19, 2026

A peptide AI, and the data it still has to make

A new University of Toronto project, OpenPep, wants to predict which peptides bind which proteins. What's interesting is where it starts: by admitting the field doesn't have the data an AI would need, and building the data first.

explainer· October 16, 2026

What teduglutide actually is, and the gut it was approved to rebuild

Teduglutide is a GLP-2 peptide that tells the intestine to grow, approved for one severe condition and monitored closely because of how it works. A plain look at the mechanism, the narrow clearance, and why its growth effect is also its warning label.

lifestyle· October 14, 2026

The table keeps time

As the light gives out in October, dinner drifts to wherever the day leaves a gap. The case for a fixed hour at the table, as a wall against the dark rather than a diet.

explainer· October 13, 2026

What bremelanotide actually is, and the receptor it shares with a tan

Bremelanotide is a melanocortin peptide, the same family as the tanning compounds, but it was aimed at the brain instead of the skin. It carries an FDA label, a modest and debated trial record, and a one-word admission in its own prescribing information: mechanism, unknown.

lifestyle· October 11, 2026

The good day is not a bonus

Most routine advice is about surviving the bad days. The harder test is the good one, when you feel great and the urge is to spend it all at once. On why the days you feel best are the ones most likely to wreck a routine.

lifestyle· October 9, 2026

The part you can't outsource

Most of what wellness sells is something you can buy. The foundation underneath it is the one thing nobody can do for you, and that's the part that actually decides the outcome.

explainer· October 7, 2026

What humanin actually is, and why it was named for a hope

Humanin was the first peptide anyone caught the mitochondria writing, pulled from neurons that survived in an Alzheimer's brain. A plain look at where it comes from, what the lab work suggests, and why its name promises more than the evidence can yet keep.

research· October 5, 2026

Growth hormone, turned down at midlife

A new Aging Cell study switched off the growth-hormone receptor in middle-aged mice and they lived modestly longer. What the result shows, why the timing is the interesting part, and the tension it creates with the peptides people take to raise the same signal.

lifestyle· October 3, 2026

A breakthrough a week

The wellness news cycle now produces a breakthrough on a schedule. On the distance between a lab result and your ordinary Tuesday, and why letting most headlines pass is the long-game move.

research· October 1, 2026

Five hundred studies, mostly mice

A new UCLA review counted 565 studies of the peptides sold for recovery and performance. More than two-thirds were done only in animals, and the human evidence for the thing people actually buy them for is thin. A look at what a careful survey of the whole shelf adds up to.

lifestyle· September 29, 2026

The active ingredient

Every protocol comparison assumes the compounds do the work. The thing that actually separates a routine that lasts from one that doesn't is whether you keep doing it. On adherence as the real mechanism.

lifestyle· September 27, 2026

Nobody starts from zero

After a chaotic stretch, wellness culture tells you to reset, rebuild, start over. On why a lapsed routine isn't a wiped one, and why treating a gap as a reset is what turns a bad month into a quit.

research· September 25, 2026

The microproteins we couldn't see

A new atlas maps over a thousand tiny proteins in the human brain that standard methods kept missing, and links some of them to Alzheimer's. What it says about the peptides the body was already running on, quietly, the whole time.

lifestyle· September 23, 2026

The walk that earns nothing

Wellness turns everything into a dose, a metric, a protocol you can tune. The daily walk resists all of it. On the one input you can't optimize, and why that's exactly the point.

explainer· September 21, 2026

What Semax actually is, and the border its evidence stops at

Semax is a short brain peptide that has been an approved medicine in Russia for years and an unapproved research chemical almost everywhere else. A plain look at what it does, where it is cleared, and why the map matters as much as the molecule.

explainer· September 19, 2026

What AOD-9604 actually is, and what its trials actually found

AOD-9604 is sold online as a fat-loss peptide with a clever origin story. A plain look at the fragment it's built from, the idea behind it, and the large trial that quietly ended its run as a weight-loss drug.

lifestyle· September 15, 2026

You can't borrow a routine

The regimen someone posts was built around their schedule, their body, and their budget, not yours. On why copied protocols quietly fail, and why the thing worth taking is the principle, never the checklist.

explainer· September 13, 2026

What Argireline actually is, and why 'Botox in a jar' is doing a lot of lifting

Argireline is the peptide behind the serums that promise a needle-free version of a wrinkle relaxer. A plain look at acetyl hexapeptide-8, the one study everyone quotes, and the delivery problem the label leaves out.

research· September 11, 2026

A hundred extra days, in mice

A Nature study gave semaglutide to old mice and they lived longer, with better muscle and memory than calorie-restricted controls. What the result actually shows, and the distance between a mouse cage and a person.

explainer· September 9, 2026

What Selank actually is, and why its evidence lives behind a wall

Selank is a rare thing in the peptide world: an anxiolytic that actually cleared a regulator. The catch is which one. A plain look at where it came from, what the trials report, and why almost all of that record sits inside a single research network.

research· September 7, 2026

Cellular reprogramming reached its first human trial, and it started in one eye

Partial reprogramming is the flashiest idea in longevity: reset a cell's age without changing what it is. In 2026 it entered its first human study. A plain look at what the trial actually tests, and how narrow that first step is.

explainer· September 3, 2026

What afamelanotide actually is

The tanning peptide has a real, FDA-approved cousin used for a rare light disorder. It is not the thing sold online, and the difference is the whole point.

explainer· September 1, 2026

What kisspeptin actually is, and why it sits so far upstream

Kisspeptin is the signal that tells the body's reproductive system to switch on. A plain look at where it sits in the chain, why researchers keep studying it, and what the recent human trials have and haven't settled.

explainer· August 31, 2026

What the tanning peptides actually are, and the line down the middle of the family

The word peptide sits on top of two very different molecules that both promise a tan. One is a regulated drug for a rare disease. The other is sold on the internet. A plain look at what separates them.

lifestyle· August 29, 2026

The tan was never the point

Late August, and the color you spent three months on starts to go. On the difference between the part of a season that fades and the part that quietly carries into the dark months.

explainer· August 27, 2026

What tesamorelin actually is, and why it asks the body to do the work

Tesamorelin is the only FDA-approved GHRH peptide, cleared for one narrow condition. A plain look at how it prompts the body to make its own growth hormone, the population it was approved for, and how far past that its reputation has traveled.

research· August 25, 2026

A two-receptor peptide aims at the liver, and heads into the trial that counts

Pemvidutide just entered Phase 3 for a fatty-liver disease called MASH. What makes it unusual is the second receptor it pulls, and why its promising mid-stage numbers still have to survive a much harder test.

explainer· August 23, 2026

What amylin actually is, and why the field circled back to it

Amylin is the other hormone your pancreas releases at every meal, discovered decades ago and mostly shelved. A plain look at what it does, why the first drug built from it went nowhere, and what changed to make it the most-watched molecule after GLP-1.

explainer· August 19, 2026

What MOTS-c actually is, and why it reads like a message from the mitochondria

MOTS-c is a tiny peptide your own mitochondria encode, it rises with exercise and falls with age, and it has become a fixture in longevity conversations. A plain look at where it comes from, what the animal work shows, and how thin the human evidence still is.

explainer· August 17, 2026

What thymosin alpha-1 actually is, and why 'modulator' is the word that matters

A fragment of what the thymus makes, thymosin alpha-1 is approved in dozens of countries and in none of them as an immune booster. A plain look at the molecule, the mechanism, and the map of where it's actually a drug.

lifestyle· August 15, 2026

What the fade is for

By mid-August the light has already turned and the color starts to go. A note on why the fade isn't a loss, and what it means to let a season close instead of clinging to its peak.

explainer· August 13, 2026

What growth-hormone peptides actually are, and the one the FDA cleared

Sermorelin, CJC-1295, ipamorelin, tesamorelin. They get lumped together as 'GH peptides,' but they work by two different routes, and only one of them carries a full FDA approval. A plain map of the category.

lifestyle· August 11, 2026

Close the tab

A blog quietly making the case that you should read fewer of them. On the point where more wellness research stops helping and starts standing in for the thing itself.

explainer· August 9, 2026

What melanocortin peptides actually are, and why the tanning two don't share a safety record

The peptides that darken skin all pull the same lever, alpha-MSH on the melanocortin-1 receptor. One of them is an FDA-approved drug for a rare disease. Another is a gray-market research chemical with a Skin Cancer Foundation warning attached. Same family, very different files.

lifestyle· August 7, 2026

The number you wake up to

A wellness score is easy to check and hard to ignore. On what happens when a daily readout quietly becomes the thing you're optimizing, and how to keep the number a servant instead of a judge.

explainer· August 5, 2026

What melanotan actually is, and where the line runs

One melanocortin peptide is an FDA-approved drug given by a doctor. Another, sold online as a tanning shortcut, is banned almost everywhere. A plain look at why they share a name and almost nothing else.

research· August 3, 2026

A narrow yes on the peptides, and the question underneath it

An FDA advisory panel voted to recommend BPC-157, KPV, TB-500 and MOTS-c for licensed compounding, over the objections of the agency's own scientists. What the close votes settled, what they left open, and why one panelist said he wasn't sure what he was voting on.

research· August 1, 2026

A cone snail's peptide, and a different way to read a pain signal

A venom peptide from a sea snail turns out to block a very specific transporter in the pain system. A new structure shows how, and why the science is interesting long before it is useful.

explainer· July 31, 2026

The peptide delivery problem, and why it decides almost everything

A recent Northeastern piece put a name to the thing that separates a promising molecule from a working drug. It isn't potency. It's whether the peptide ever reaches the place it's supposed to work.

research· July 29, 2026

Six of seven: the peptide vote is in

An FDA advisory committee recommended six of seven popular peptides for the compounding list, against the advice of the agency's own scientists. What the vote settled, what it didn't, and why a recommendation is still not a result.

research· July 27, 2026

The panel voted yes. The agency's own scientists voted no.

An FDA advisory committee recommended easing compounding restrictions on several popular peptides. The agency's career scientists argued the evidence wasn't there. What the split vote decides, and what it doesn't.

research· July 25, 2026

The committee voted. It didn't rubber-stamp.

The FDA's compounding advisory committee finally weighed in on seven popular peptides. Six were recommended, one was turned down, and a couple of the votes were close. The split is more useful than the headline.

lifestyle· July 23, 2026

The only fair comparison

Wellness quietly turns everything into a leaderboard: whose skin, whose sleep, whose protocol. The one comparison that actually tells you something is you against your own past. On keeping your own ledger.

research· July 21, 2026

Peptides and skin: the biggest pooled look yet, and its fine print

A 2026 meta-analysis gathered 19 randomized trials of peptides for skin aging into one estimate. The headline is that peptides helped. The interesting part is which peptides, given which way, and how much the trials disagreed.

research· July 19, 2026

Trained older muscle read younger. The study is careful about why.

A Nature Aging study read the muscle of young and older adults down to the gene, and found that half the usual age gap was simply absent in people who trained. What that means, and the causal line the data can't cross.

lifestyle· July 17, 2026

The case for subtraction

Most wellness advice adds one more thing. The more useful move is usually to take something away. On pruning a routine down to what actually earns its place.

explainer· July 15, 2026

What DSIP actually is, and the gap between its name and its evidence

DSIP is sold as a sleep peptide, and the name says so outright. A plain look at where it came from, what the human trials found, and why a molecule named for deep sleep has such a mixed record at producing it.

explainer· July 13, 2026

What Epitalon actually is, and why one replication matters

Epitalon is the longevity peptide with the biggest mythology and one of the thinnest evidence files. A look at where it came from, what a 2025 independent study did and didn't show, and why longer telomeres are not a simple win.

explainer· July 11, 2026

What SS-31 actually is, and the one thing it's approved for

SS-31, or elamipretide, is the first mitochondria-targeted peptide the FDA has approved. A plain look at what it does inside the cell, the narrow condition it's cleared for, and why the trials that aimed wider mostly came up short.

research· July 9, 2026

A mitochondrial peptide got approved. Read what it's approved for.

Elamipretide, the molecule longevity circles know as SS-31, cleared the FDA in late 2025. It's the first cardiolipin-directed mitochondrial therapeutic to reach market, and the details of the approval say more than the headline does.

research· July 7, 2026

The peptide craze meets a hard question

A June Nature feature asked whether the peptide boom is backed by science. The answer, from one of the field's founders, was careful in a way worth borrowing.

lifestyle· July 5, 2026

The results you can't feel

Most of the things worth doing for the long game give you no daily sensation of working. A look at why the missing feedback loop is what quietly ends most routines, and what to anchor to instead.

lifestyle· July 3, 2026

Built for the bad day

Most routines are designed for the version of you who slept well and has time. The one that lasts is the one that still works on the worst day of the month. A case for building to the floor, not the ceiling.

research· July 1, 2026

Retatrutide's first big trial, and the tradeoff hiding in the number

The triple agonist retatrutide posted its first pivotal Phase 3 result. A look at what TRIUMPH-1 actually measured, why the top-line figure is only half the story, and what the trial leaves unanswered.

explainer· June 29, 2026

What TB-500 actually is, and the gap between the fragment and the research

TB-500 is the recovery half of the so-called Wolverine stack. A plain look at what it is, how it differs from the thymosin-β4 molecule it's named after, and where the human evidence runs out.

research· June 27, 2026

The new GLP-1 pills, and why most of them aren't peptides

A wave of oral GLP-1 drugs reported strong phase 2 data at this year's diabetes meeting. The quiet detail worth noticing: the field's most famous peptide is being re-engineered into something that isn't one.

explainer· June 25, 2026

What a biological age test actually measures

Mail-in kits now promise to tell you how old your body really is. A plain look at what those numbers are reading, why two clocks can disagree about the same person, and how much weight a single result deserves.

research· June 23, 2026

Semaglutide and the aging clocks: a small, careful result

A placebo-controlled trial found semaglutide slowed several epigenetic measures of aging. What the clocks actually track, what the result says, and the line the researchers refused to cross.

lifestyle· June 21, 2026

One thing at a time

The instinct in wellness is to stack: add the serum, the supplement, the new habit, all at once. A quieter case for changing one thing and waiting long enough to actually know what it did.

lifestyle· June 19, 2026

The off-season nobody schedules

Serious athletes plan their rest as carefully as their training. Most of us treat recovery as whatever's left over. A case for building the rhythm in on purpose.

explainer· June 17, 2026

What copper peptides actually are, and what the skin studies show

Copper peptides are a fixture of the serum aisle. A plain look at what GHK-Cu is, why it occurs in your own blood, and how to read the cosmetic evidence without rounding up.

research· June 15, 2026

The biggest collagen review yet, and the line it won't cross

Researchers pooled 16 reviews and 113 trials into the largest evidence synthesis on collagen to date. A look at what it found for skin, joints, and muscle, and where it stops short.

research· June 13, 2026

The rules are loosening. The evidence isn't.

The FDA is reviewing whether several popular peptides can move back toward licensed compounding. A plain look at what that process decides, what it doesn't, and why wider access is not the same as stronger proof.

lifestyle· June 11, 2026

Both ends of the sleep curve

A large UK Biobank analysis points to a narrow window where sleep tracks with slower organ aging. The interesting part isn't the floor. It's that there's a ceiling too.

lifestyle· June 9, 2026

The clock you can't see, and the light that sets it

The sun is in our name, so here is an honest look at the role light plays beyond skin: it's the main signal the body uses to keep time. What the research describes, and how a calmer relationship with morning light fits the long game.

explainer· June 7, 2026

What BPC-157 actually is, and what the evidence isn't

BPC-157 is everywhere in recovery circles. A plain look at what the peptide is, what the animal research suggests, and why a 2025 review still calls it investigational.

explainer· June 5, 2026

BPC-157 and the distance between a forum and a trial

BPC-157 is one of the most talked-about peptides online and one of the least studied in people. A plain look at what it is, where its evidence actually comes from, and why the regulators stepped in.

research· June 3, 2026

The muscle question hiding inside the GLP-1 boom

A new mouse study takes aim at lean-mass loss during rapid weight loss. A look at what the result shows, what it doesn't, and why the question matters for aging well.

explainer· June 2, 2026

What people mean when they say "collagen peptides"

The word peptide gets stretched across very different products. A plain-English look at what collagen peptides are, how the oral kind is absorbed, and how to read the evidence.

lifestyle· June 1, 2026

The long game

Why we build for decades instead of weeks, and what a slower approach to skin, recovery, and energy actually looks like day to day.

research· May 30, 2026

How to read peptide research without fooling yourself

A practical, non-technical guide to evaluating early-stage research claims so you can tell a strong finding from a hopeful headline.